421 reports of this reaction
1.8% of all DALTEPARIN SODIUM reports
#11 most reported adverse reaction
GENERAL PHYSICAL HEALTH DETERIORATION is the #11 most commonly reported adverse reaction for DALTEPARIN SODIUM, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 421 FDA adverse event reports linking DALTEPARIN SODIUM to GENERAL PHYSICAL HEALTH DETERIORATION. This represents approximately 1.8% of all 23,703 adverse event reports for this drug.
Patients taking DALTEPARIN SODIUM who experience general physical health deterioration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GENERAL PHYSICAL HEALTH DETERIORATION is a less commonly reported adverse event for DALTEPARIN SODIUM, but still significant enough to appear in the safety profile.
In addition to general physical health deterioration, the following adverse reactions have been reported for DALTEPARIN SODIUM:
The following drugs have also been linked to general physical health deterioration in FDA adverse event reports:
GENERAL PHYSICAL HEALTH DETERIORATION has been reported as an adverse event in 421 FDA reports for DALTEPARIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
GENERAL PHYSICAL HEALTH DETERIORATION accounts for approximately 1.8% of all adverse event reports for DALTEPARIN SODIUM, making it a notable side effect.
If you experience general physical health deterioration while taking DALTEPARIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.